SYMBOL CHANGE ON OTC MARKETS TO “BRAXF"
BRAXIA SCIENTIFIC ANNOUNCES SYMBOL CHANGE ON OTC MARKETS TO “BRAXF” In Quebec, ~20% of the population, or 1 in 5 people, experience mental illness during their lifetime; Covid-19 has further exacerbated the number of adults experiencing symptoms of major depression This joint venture creates first privately owned clinic in Quebec to address unmet need for accessible, high-quality, advanced mental health services and treatments for depression, suicide, and other mental health disorders including providing access to rapid-onset treatments such as Intravenous ketamine Established in 2006, Neurotherapy Montreal provides access to large network of physicians across Quebec, including +1,200 psychiatrists Neurotherapy Montreal’s large, established patient base includes patients diagnosed with brain-based injuries such as Anxiety, Depression, Attention Deficit Hyperactivity Disorder (ADHD), Traumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Chronic Pain, Vestibular and Sleep Disorder The Braxia clinic is situated...
FIRST KETAMINE THERAPY CLINIC IN QUEBEC
In Quebec, ~20% of the population, or 1 in 5 people, experience mental illness during their lifetime; Covid-19 has further exacerbated the number of adults experiencing symptoms of major depression This joint venture creates first privately owned clinic in Quebec to address unmet need for accessible, high-quality, advanced mental health services and treatments for depression, suicide, and other mental health disorders including providing access to rapid-onset treatments such as Intravenous ketamine Established in 2006, Neurotherapy Montreal provides access to large network of physicians across Quebec, including +1,200 psychiatrists Neurotherapy Montreal’s large, established patient base includes patients diagnosed with brain-based injuries such as Anxiety, Depression, Attention Deficit Hyperactivity Disorder (ADHD), Traumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Chronic Pain, Vestibular and Sleep Disorder The Braxia clinic is situated within a 14,000 square foot multi-disciplinary state of the art...
BRAXIA SCIENTIFIC INTRODUCES “BRAXIA HEALTH”
BRAXIA SCIENTIFIC INTRODUCES “BRAXIA HEALTH” A GROWING NETWORK OF CLINICS LEADING NOVEL PSYCHEDELIC RESEARCH AND TREATMENTS FOR MENTAL DISORDERS Braxia Scientific enters a new chapter as it commences trading under its new ticker “CSE: BRAX” and rebrands its growing network of leading clinics to Braxia Health, which includes the Canadian Rapid Treatment Centre of Excellence established in 2018. Only clinic in Canada previously involved in a randomized controlled pivotal trial for regulatory approval purposes of psilocybin for the treatment of adults with depression. Led by Dr. Roger McIntyre, the top-rated expert in depression since 2010 as rated by Expertscape, Braxia Health has the largest clinical research footprint for ketamine and psychedelic-based research in the world, providing the fastest route to development of its IP capable formulations and IP capable delivery methods. First community-based centre in Canada to specialize in rapid-acting treatments...
COMMENTS ON PROSPECTIVE CLASS PROCEEDING
BRAXIA SCIENTIFIC CORP. COMMENTS ON PROSPECTIVE CLASS PROCEEDING TORONTO, ONTARIO May 3, 2021 – Braxia Scientific Corp. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), (formerly Champignon Brands Inc.) announces that it was served with a notice of civil claim in a proposed class proceeding in British Columbia against the Company, its CEO, certain of its former officers, a shareholder, and underwriters which were engaged in connection with a private placement financing for the Company in June 2020. The Company has accepted service as of today’s date. The claim is based on allegations relating to the Company’s disclosure documents regarding the value of four acquisitions made by the Company in 2020 and related matters. The plaintiff is seeking an unspecified amount of damages for the proposed class. The Company intends to vigorously defend the claim. About Braxia Scientific Corp. Braxia...
CHANGES NAME TO BRAXIA SCIENTIFIC CORP
CHAMPIGNON BRANDS CHANGES NAME TO BRAXIA SCIENTIFIC TO REFLECT THE INTEGRATION OF KETAMINE AND PSYCHEDELIC CLINICS AND ITS RESEARCH AND DEVELOPMENT PRIORITIES TORONTO, ONTARIO May 3, 2021 – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), is pleased to announce that it has changed its name from “Champignon Brands Inc.” to “Braxia Scientific Corp.” and its ticker symbol will change from “SHRM” to “BRAX” on the Canadian Securities Exchange (the “CSE”). The name change reflects the Company’s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company’s ketamine and psychedelic derivative research and drug development priorities. Braxia Scientific’s overarching aim is to shape the future of treatment for people suffering from depression and other mental health disorders. “Our new...
REVOCATION OF CEASE TRADE ORDERS
TORONTO, ONTARIO April 22, 2021 - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), is pleased to announce that the British Columbia Securities Commission and Ontario Securities Commission (the “Commissions”) have revoked their cease trade orders against the Company effective April 22, 2021.
CHAMPIGNON BRANDS ANNOUNCES FILING OF LISTING STATEMENT
TORONTO, ONTARIO, March 26, 2021 /CNW Telbec/ - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced today that it has filed a new Listing Statement with the Canadian Securities Exchange ("CSE") which contains disclosure regarding the acquisition of AltMed Capital Corp. (“AltMed”) (the “Transaction”). The Transaction constituted a reverse takeover of Champignon by AltMed.
RESTATES FINANCIAL STATEMENTS AND MD&A LISTING
VANCOUVER, BRITISH COLUMBIA – March 11, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced that as a result of a review by the British Columbia Securities Commission (the “Commission”), the Company has refiled its condensed interim consolidated financial statements and management’s discussion & analysis (“MD&A”) for the three and six month periods ended March 31, 2020 (the “Restated Financial Statements and MD&A”).
CSE LISTING STATEMENT
VANCOUVER, BRITISH COLUMBIA – February 17, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced that as a result of a review by the British Columbia Securities Commission (the “Commission”), the Company has determined to withdraw and refile its condensed interim consolidated financial statements and management’s discussion & analysis (“MD&A”) for the three and six month periods ended March 31, 2020 (the “Original Financial Statements and MD&A”).
DR. ROGER MCINTYRE ANNOUNCES CHANGES TO THE BOARD
VANCOUVER, BRITISH COLUMBIA, February 4, 2021 - Dr. Roger McIntyre, Chairman of the Board of Directors of Champignon Brands Inc. today announces changes to the Champignon Board of Directors (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF).
NEW RAPID MOOD SCREENER (RMS) SCREENS
VANCOUVER, BRITISH COLUMBIA – February 3, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announces the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc.
CENTRE IN OTTAWA TO PROVIDE KETAMINE TREATMENT DEPRESSION
VANCOUVER, BRITISH COLUMBIA – Monday, January 25, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario.